AI assistant
HAEMONETICS CORP — Director's Dealing 2021
Aug 25, 2021
31565_dirs_2021-08-25_db3d485c-55ca-4353-8bb9-e08c221ca856.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-08-23
Reporting Person: Burke William P. Mr. (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-23 | Common Stock | M | 11232 | $34.21 | Acquired | 41523 | Direct |
| 2021-08-23 | Common Stock | M | 11435 | $41.64 | Acquired | 52958 | Direct |
| 2021-08-23 | Common Stock | S | 22667 | $60.51 | Disposed | 30291 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-23 | Non-qualified Stock Option (Right to Buy) | $34.21 | M | 11232 | Disposed | 2023-10-25 | Common Stock (11232) | Direct |
| 2021-08-23 | Non-qualified Stock Option (Right to Buy) | $41.64 | M | 11435 | Disposed | 2024-06-06 | Common Stock (11435) | Direct |
Footnotes
F1: Transaction pursuant to an existing 10b5-1 trading plan.
F2: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: This number includes unvested RSUs previously reported.